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derived from the ﬁve dimensions of the EQ-5D (mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression).
A single utility score on an interval metric was provided by the
application of health state evaluations. Individual differences in
clinical outcome trajectories were modeled using latent curve
models that captured linear and non-linear trends over time for
SOHO participants. Model estimation used Maximum Likeli-
hood methods in Mplus software and therefore enabled inclu-
sion of missing data under a Missing At Random (MAR)
assumption. RESULTS: EQ-5D utility scores could not be 
adequately summarised by simple linear models over two years.
Instead models allowing for curvilinear trajectories were
required. The fastest change in EQ-5D utility scores occurred in
the six months after medication initiation or change. Some indi-
viduals with later relapses were also identiﬁed by turning points
in their outcome trajectory. CONCLUSIONS: New statistical
methods for latent growth modeling are useful tools for dis-
playing and modeling individual variations in clinical and social
outcomes, including self-rated quality of life, in schizophrenia
patients. In future work we hope to relate these proﬁles to pat-
terns of medication change.
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OBJECTIVES: LOGIC (Longitudinal Outcomes study of Gas-
trointestinal symptoms in Canada) and ILOS (Irritable bowel
syndrome Longitudinal Outcomes Study) are two ongoing phar-
macoepidemiologic studies of patients with irritable bowel syn-
drome with constipation or alternating constipation/diarrhea
(IBS-C or IBS-A) across Canada and the US, respectively. The
purpose was to develop and validate a self-report questionnaire
that measures severity of IBS symptoms in patients with IBS-C
and IBS-A. METHODS: The IBS patient’s symptoms question-
naire was a 15-item questionnaire that measured frequency,
intensity, and distress/bother associated with the following IBS
symptoms: constipation, gas, abdominal pain/discomfort, bloat-
ing, and diarrhea. All items were measured on a 0 to 5-point
scale except for the frequency items from the ILOS study, which
were measured on a 0 to 4-point scale. To explore the question-
naire items, a principal component analysis (PCA) was per-
formed. Correlations between the baseline severity scores and the
baseline IBS-QOL overall scores were calculated. RESULTS: To
date, 1557 subjects have provided the IBS severity of symptoms
questionnaire at baseline for LOGIC. The PCA showed that
three components provide a good summary of the data, with the
1st, 2nd, and 3rd components accounting for 37%, 20%, and
13% of the total variability in the data, respectively. Similar PCA
results were observed for the 380 subjects who provided the
ILOS questionnaire. For both studies, the ﬁrst component
approximates a simple average of scores for items of all symp-
toms excluding diarrhea. The resulting Severity Score signiﬁ-
cantly correlates with the IBS-QOL total score with r = -0.549
(p < 0.001) for LOGIC and r = -0.468 (p < 0.001) for ILOS.
CONCLUSIONS: Although more extensive testing of the ques-
tionnaire is required, the IBS Severity questionnaire seems too
efﬁciently and comprehensively measure patient severity of IBS
symptoms. The Severity Score appears to be an effective measure
of overall severity for subjects with IBS-C or IBS-A.
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OBJECTIVES: Interventions that increase compliance with med-
ication may improve outcomes in schizophrenia, but need to be
targeted on groups at high risk for non-adherence behaviours.
The aims of this study were 1) to deﬁne latent adherence classes,
one year after antipsychotic medication change or initiation, and
2) to examine predictors of class membership from clinical and
treatment variables recorded one year earlier. METHODS:
Latent class analysis was applied to indicators of compliance
behaviour twelve months after new antipsychotic medication
was initiated or existing medication changed. The sample com-
prised 1,736 patients with schizophrenia sampled from the seven
drug cohorts participating in the Schizophrenia Outpatient
Health Outcomes (SOHO) observational study of health out-
comes of antipsychotic treatment (n = 10,218). RESULTS: Over
three quarters of the SOHO sample were highly compliant 
with antipsychotic medication. 19% were identiﬁed by the 
model as non-adherent. In addition to treatment cohort, drug
abuse (adj OR = 1.69, 95% CI 1.07–2.65), alcohol abuse (adj
OR = 1.61, 95% CI 1.03–2.53) or hospital admission (adj OR
= 1.97 95% CI 1.43–2.71) prior to study entry predicted non-
adherence class membership one year later. CONCLUSIONS:
Latent classiﬁcation analyses identiﬁed a patient group at risk
for poor medication compliance that could be targeted with
interventions to increase adherence behaviours. Further reﬁne-
ments of this classiﬁcation may identify a continuum of compli-
ance behaviours.
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OBJECTIVE: The Q-TWiST (Quality-Adjusted Time Without
Symptoms or Toxicity) method compares treatments for time
spent in clinically different health states that vary by patient
utility (toxicity, symptom-free period and disease relapse).
Kaplan-Meier or Cox model-based estimators of transition times
between states are generated separately to account for censoring
and loss to follow-up. Q-TWiST is then calculated as a weighted
sum of mean health state durations and its variance is calculated
using the bootstrap method. The methodology is well-accepted
in oncology research, but has been used infrequently in other
therapeutic areas. Application is restricted to time-sensitive out-
comes and to well-controlled clinical trials. METHODS: We
present a new approach to calculate Q-TWiST and its variance
using a repeated measures framework in a multivariate failure
time regression model (Wei, Lin, Weissfeld, 1989). First, a single
likelihood function that incorporates multiple events is derived
and event-speciﬁc parameters are then estimated simultaneously
by maximizing the likelihood function. Once the parameter esti-
mates are obtained, the robust variance-covariance matrix is
easily computed, incorporating within-patient correlations of
event times. The utility-weighted Q-TWiST and its variance are
derived by the delta method utilizing the estimated parameters
